Abstract
With increased survival after pediatric allogeneic hematopoietic SCT health-related quality of life (HRQL) has emerged as an essential health outcome. The impact of transplant and chronic GVHD (cGVHD)-associated morbidity remains a major obstacle. In 2005, the National Institutes of Health (NIH) Consensus Conference on Criteria for Clinical Trials in cGVHD recommended HRQL tools as an independent measure of the impact of disease burden. The NIH recommendations did not provide a cGVHD-specific tool for HRQOL measures in children. This report focuses on the development of an SCT-specific instrument to assess HRQL in children and adolescents. For the assessment of generic HRQL we chose the PedsQL (Pediatric Quality of Life Inventory) Generic Cores Scales, which have been used in a large number of healthy, acutely ill and chronically ill children and adolescents. To capture SCT- and, specifically, cGVHD-related problems, we developed the PedsQL Stem Cell Transplant module by reviewing the literature, taking over some items/scales of other PedsQL modules, interviewing patients, parents and members of the health-care team, and applying the PedsQL measurement methods. The final PedsQL Stem Cell Transplant module consists of the HRQL domains: pain and hurt, fatigue/sleeping problems/weakness, nausea, worry/anxiety about disease/treatment, nutritional problems, neurocognitive problems, communication about disease/treatment, loneliness, physical functioning and additional somatic complaints (pruritus, skin inflammation, oral problems, eyes or breathing) including patients’ and parents’ assessment. It was tested in 35 pediatric patients, who were referred to our SCT Outpatient Clinic about 100 days post SCT. Both the generic PedsQL and the SCT-specific scales showed high internal consistency, with Cronbach alpha levels of ⩾0.70 in almost all scales. Most problems were detected within the HRQL domains of physical functioning and pain. The summary scores of the generic PedsQL and the PedsQL Stem Cell Transplant module showed high correlations (r=0.89 in patients’ and r=0.81 in parents’ assessments). Moreover, both tools discriminated between patients with and without cGVHD. The PedsQL Stem Cell Transplant module is practical for use and suitable across a broad age range (2–18 years) both in patients with and without cGVHD. However, it is still a pilot instrument and needs further development and testing in a larger patient population.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11: 945–956.
Pavletic SZ, Lee SJ, Socie G, Vogelsang G . Chronic graft-versus-host disease: implications of the National Institutes of Health consensus development project on criteria for clinical trials. Bone Marrow Transplant 2006; 38: 645–651.
Pavletic SZ, Martin P, Lee SJ, Mitchell S, Jacobsohn D, Cowen EW et al. Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report. Biol Blood Marrow Transplant 2006; 12: 252–266.
Varni JW, Burwinkle TM, Katz ER, Meeske K, Dickinson P . The PedsQL in pediatric cancer: reliability and validity of the Pediatric Quality of Life Inventory Generic Core Scales, Multidimensional Fatigue Scale, and Cancer Module. Cancer 2002; 94: 2090–2106.
Varni JW, Burwinkle TM, Seid M, Skarr D . The PedsQL 4.0 as a pediatric population health measure: feasibility, reliability, and validity. Ambul Pediatr 2003; 3: 329–341.
Felder-Puig R, Baumgartner M, Topf R, Gadner H, Formann AK . Health-related quality of life in Austrian elementary school children. Med Care 2008; 46: 432–439.
Felder-Puig R, di Gallo A, Waldenmair M, Norden P, Winter A, Gadner H et al. Health-related quality of life of pediatric patients receiving allogeneic stem cell or bone marrow transplantation: results of a longitudinal, multi-center study. Bone Marrow Transplant 2006; 38: 119–126.
Felder-Puig R, Frey E, Proksch K, Varni JW, Gadner H, Topf R et al. Validation of the German version of the Pediatric Quality of Life Inventory (PedsQL) in childhood cancer patients off treatment and children with epilepsy. Qual Life Res 2004; 13: 223–234.
Weissberg-Benchell J, Zielinski TE, Rodgers S, Greenley RN, Askenazi D, Goldstein SL et al. Pediatric health-related quality of life: feasibility, reliability and validity of the PedsQL™ transplant module. Am J Transplant 2010; 10: 1686–1694.
Cheuk DKL, Mok ASP, Lee ACW, Chiang AKS, Ha SY, Lau YL et al. Quality of life in patients with transfusion-dependent thalassemia after hematopoietic SCT. Bone Marrow Transplant 2008; 42: 319–327.
Caocci G, Efficace F, Ciotti F, Roncarolo MG, Vacca A, Piras E et al. Prospecitve assessment of health-related quality of life in pediatric patients with beta-thalassemia following hmeatopoietic stem cell transplantation. Biol Blood Marrow Transplant 2011; 17: 861–866.
Uzark K, Grifin L, Rodiguez R, Zamberlan M, Murphy P, Nasman C et al. Quality of life in pediatric heart transplant recipients: a comparison with children with and without heart disease. J Heart Lung Transplant 2012; 31: 571–578.
Goldstein SL, Graham N, Burwinkle T, Warady B, Farrah R, Varni JW et al. Health-related quality of life in pediatric patients with ESRD. Pediatr Nephrol 2006; 21: 846–850.
Goldstein SL, Graham N, Warady BA, Seikaly M, McDonald R, Burwinkle TM et al. Measuring health-related quality of lie in children with ESRD: performance of the generic and ESRD-specific instrument of the Pediatric Quality of Life Inventory™ (PedsQL™). Am J Kidney Dis 2008; 51: 285–297.
Goldstein SL, Rosburg NM, Warady BA, Seikaly M, McDonald R, Limbers C et al. Pediatric end stage renal disease health-related quality of life differs by modality: a PedsQL ESRD analysis. Pediatr Nephrol 2009; 24: 1553–1560.
Greinix HT, Loddenkemper C, Pavletic SZ, Holler E, Socie G, Lawitschka A et al. Diagnosis and staging of chronic graft-versus-host disease in the clinical practice. Biol Blood Marrow Transplant 17: 167–175.
Baker KS, Fraser CJ . Quality of life and recovery after graft-versus-host disease. Best Pract Res Clin Haematol 2008; 21: 333–341.
Fraser CJ, Bhatia S, Ness K, Carter A, Francisco L, Arora M et al. Impact of chronic graft-versus-host disease on the health status of hematopoietic cell transplantation survivors: a report from the Bone Marrow Transplant Survivor Study. Blood 2006; 108: 2867–2873.
Couriel D, Carpenter PA, Cutler C, Bolanos-Meade J, Treister NS, Gea-Banacloche J et al. Ancillary therapy and supportive care of chronic graft-versus-host disease: national institutes of health consensus development project on criteria for clinical trials in chronic Graft-versus-host disease: V. Ancillary Therapy and Supportive Care Working Group report. Biol Blood Marrow Transplant 2006; 12: 375–396.
Schultz KR, Miklos DB, Fowler D, Cooke K, Shizuru J, Zorn E et al. Toward biomarkers for chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: III. Biomarker Working Group report. Biol Blood Marrow Transplant 2006; 12: 126–137.
Shulman HM, Kleiner D, Lee SJ, Morton T, Pavletic SZ, Farmer E et al. Histopathologic diagnosis of chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. Pathology Working Group report. Biol Blood Marrow Transplant 2006; 12: 31–47.
Kopp M, Schweigkofler H, Holzner B, Nachbaur D, Niederwieser D, Fleischhacker WW et al. EORTC QLQ-C30 and FACT-BMT for the measurement of quality of life in bone marrow transplant recipients: a comparison. Eur J Haematol 2000; 65: 97–103.
Lee S, Cook EF, Soiffer R, Antin JH . Development and validation of a scale to measure symptoms of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2002; 8: 444–452.
McQuellon RP, Russell GB, Cella DF, Craven BL, Brady M, Bonomi A et al. Quality of life measurement in bone marrow transplantation: development of the Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT) scale. Bone Marrow Transplant 1997; 19: 357–368.
Pallua S, Giesinger J, Oberguggenberger A, Kemmler G, Nachbaur D, Clausen J et al. Impact of GvHD on quality of life in long-term survivors of haematopoietic transplantation. Bone Marrow Transplant 45: 1534–1539.
De Civita M, Regier D, Alamgir AH, Anis AH, Fitzgerald MJ, Marra CA et al. Evaluating health-related quality-of-life studies in paediatric populations: some conceptual, methodological and developmental considerations and recent applications. Pharmacoeconomics 2005; 23: 659–685.
Wiener L, Baird K, Crum C, Powers K, Carpenter P, Scott Baker K et al. Child and parent perspectives of the chronic graft-versus-host disease (cGVHD) symptom experience: a concept elicitation study. Support Care Cancer 2014; 22: 295–305.
Acknowledgements
This study was supported by a grant from Fonds der Stadt Wien für Innovative Interdisziplinäre Krebsforschung, Vienna, Austria
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Lawitschka, A., Güclü, E., Varni, J. et al. Health-related quality of life in pediatric patients after allogeneic SCT: development of the PedsQL Stem Cell Transplant module and results of a pilot study. Bone Marrow Transplant 49, 1093–1097 (2014). https://doi.org/10.1038/bmt.2014.96
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2014.96
This article is cited by
-
Impact of chronic GVHD on QOL assessed by visual analogue scale in pediatric HSCT survivors and differences between raters: a cross-sectional observational study in Japan
International Journal of Hematology (2022)
-
Does allogeneic stem cell transplantation in survivors of pediatric leukemia impact regular physical activity, pulmonary function, and exercise capacity?
Molecular and Cellular Pediatrics (2021)
-
Health-related quality of life predicts length of hospital stay and survival rates for pediatric patients receiving allogeneic hematopoietic cell transplantation
Quality of Life Research (2021)
-
Psychometric properties of the Activities Scale for Kids-performance after allogeneic hematopoietic stem cell transplantation in adolescents and children
Wiener klinische Wochenschrift (2021)
-
Reliability and validity of the Chinese mandarin version of PedsQL™ 3.0 transplant module
Health and Quality of Life Outcomes (2016)